Regeneron (REGN) Tops Q2 EPS by $1.17

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Regeneron (REGN) Tops Q2 EPS by $1.17

Regeneron Reports Second Quarter 2022 Financial and Operating Results

August 3, 2022 6:30 AM EDT

Second quarter 2022 revenues decreased 44% to $2.86 billion versus second quarter 2021; excluding REGEN-COV®(a)(b), revenues increased 20%Second quarter 2022 EYLEA® U.S. net sales increased 14% versus second quarter 2021 to a record $1.62 billionSecond quarter 2022 Dupixent® global net sales(c)(recorded by Sanofi) increased 40% to $2.09 billion versus second quarter 2021Second quarter 2022 GAAP diluted EPS of $7.47; non-GAAP diluted EPS(a) of $9.77 including unfavorable $1.71 impact from acquired IPR&D chargesFDA approved Dupixent for atopic dermatitis in children aged 6 months to 5 years and eosinophilic esophagitis in adults and adolescents; FDA priority review granted for prurigo... More